Background: Nasal polyposis is an inflammatory disorder involving the mucosa of the nose and paranasal sinuses and affecting approximately 2–4% of the general population. Methods: A literature search of Medline and Embase was conducted to obtain an overview of the epidemiology, pathophysiology, and current treatment of nasal polyposis, focusing on evidence-based efficacy of intranasal corticosteroids (INSs) as primary and postoperative therapy. Recent research on INSs in nasal polyp treatment, along with notable historic findings, was reviewed. Results: Nasal polyps are mostly characterized by eosinophil infiltration, a complex inflammation of nasal mucosa, and possibly production of polyclonal IgE. Current treatment modalities include INSs, oral corticosteroids, and surgery; surgery is generally limited to those with an insufficient response to medical treatment. Because of their effects on eosinophil-dominated inflammation, INSs and oral corticosteroids are the primary medical treatment strategies. The very low (≤1%) systemic bioavailability of newer INSs minimizes the systemic adverse effects seen with oral corticosteroids. Conclusion: Based on randomized, controlled trials, guidelines recommend INSs as first-line therapy for nasal polyps and for care after polypectomy. Clinical data suggest INSs are effective in reducing polyp size and relieving nasal symptoms. INS treatment has also reduced nasal polyp recurrence in patients undergoing functional endoscopic sinus surgery. Treatment with these mainstay options has been found to improve quality of life, which, along with symptom improvement, is a key factor in disease treatment.

Keywords:
Eosinophils, Inflammation, Intranasal corticosteroids, Nasal polyposis
1.
Krouse J, Naclerio R, Friedman HS: Patterns of care and associated costs for treating patients with nasal polyps. Poster presented at the XXV Congress of the European Academy of Allergology and Clinical Immunology, Vienna, 2006.
2.
Stjärne P: Mometasone furoate nasal spray for nasal polyposis. Expert Rev Resp Med 2007;1:187–196.
3.
Hedman J, Kaprio J, Poussa T, Nieminen MM: Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717– 722.
4.
Johansson L, Åkerlund A, Melen I, Bende M: Prevalence of nasal polyps in adults: the Skövde population-based study. Ann Otol Rhinol Laryngol 2003;112:625–629.
5.
Klossek JM, Neukirch F, Pribil C, Jankowski R, Serrano E, Chanal I, El Hasnaoui A: Prevalence of nasal polyposis in France: a cross-sectional, case-control study. Allergy 2005;60:233–237.
6.
Busaba NY, Sin HJ, Salman SD: Impact of gender on clinical presentation of chronic rhinosinusitis with and without polyposis. J Laryngol Otol 2008;10:1–5.
7.
Collins MM, Pang Y-T, Loughran S, Wilson JA: Environmental risk factors and gender in nasal polyposis. Clin Otolaryngol Allied Sci 2002;27:314–317.
8.
Fokkens W, Lund V, Mullol J; on behalf of the European Position Paper on Rhinosinusitis and Nasal Polyps group: EP30S: European position paper on rhinosinusitis and nasal polyps. Rhinol Suppl 2007;20:1–136.
9.
Mygind N, Dahl R, Bachert C: Nasal polyposis, eosinophil dominated inflammation, and allergy. Thorax 2000;55(suppl 2):S79–S83.
10.
Settipane GA: Epidemiology of nasal polyps. Allergy Asthma Proc 1996;17:231–236.
11.
Settipane GA, Chafee FH: Nasal polyps in asthma and rhinitis. A review of 6,037 patients. J Allergy Clin Immunol 1977;59:17–121.
12.
Bachert C, Hörmann K, Mösges R, Rasp G, Riechelmann H, Müller R, Luckhaupt H, Stuck BA, Rudack C: An update on the diagnosis and treatment of sinusitis and nasal polyposis. Allergy 2003;58:176–191.
13.
Small CB, Hernandez J, Reyes A, Schenkel E, Damiano A, Stryszak P, Staudinger H, Danzig M: Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J Allergy Clin Immunol 2005;116:1275–1281.
14.
Small CB, Stryszak P, Danzig M, Damiano A: Onset of symptomatic effect of mometasone furoate nasal spray in the treatment of nasal polyposis. J Allergy Clin Immunol 2008;121:928–932.
15.
Radenne F, Lamblin C, Vandezande LM, Tillie-Leblond I, Darras J, Tonnel AB, Wallaert B: Quality of life in nasal polyposis. J Allergy Clin Immunol 1999;103:79–84.
16.
Alobid I, Benítez P, Bernal-Sprekelsen M, Roca J, Alonso J, Picado C, Mullol J: Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy 2005;60:452–458.
17.
Mygind N: Advances in the medical treatment of nasal polyps. Allergy 1999;54:12–16.
18.
Bachert C, Watelet J-B, Gevaert P, Van Cauwenberge P: Pharmacological management of nasal polyposis. Drugs 2005;65:1537–1552.
19.
Ebell MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewigman B, Bowman M: Strength of recommendation taxonomy (SORT): A patient-centered approach to grading evidence in the medical literature. Am Fam Physician 2004;69:548–556.
20.
Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, Liberati A, O’Connell D, Oxman AD, Phillips B, Schünemann H, Edejer TT, Vist GE, Williams JW Jr, GRADE Working Group: Systems for grading the quality of evidence and the strength of recommendations. I. Critical appraisal of existing approaches. The Grade Working Group. BMC Health Serv Res 2004;4:38.
21.
Stoop AE, van der Heijden HA, Biewenga J, van der Baan S: Eosinophils in nasal polyps and nasal mucosa: an immunohistochemical study. J Allergy Clin Immunol 1993;91:616–622.
22.
Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P: Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol 2001;107:607–614.
23.
Davidsson A, Hellquist HB: The so-called ‘allergic’ nasal polyp. ORL J Otorhinolaryngol Relat Spec 1993;55:30–35.
24.
Lacroix JS, Zheng CG, Goytom SH, Landis B, Szalay-Quinodoz I, Malis DD: Histological comparison of nasal polyposis in black African, Chinese and Caucasian patients. Rhinology 2002;40:118–121.
25.
Zhang N, Holtappels G, Claeys C, Huang G, van Cauwenberge P, Bachert C: Pattern of inflammation and impact of Staphylococcus aureus enterotoxins in nasal polyps from southern China. Am J Rhinol 2006;20:445–450.
26.
Zhang N, Van Zele T, Perez-Novo C, Van Bruaene N, Holtappels G, DeRuyck N, Van Cauwenberge P, Bachert C: Different types of T effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol 2008;122:961–968.
27.
Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, Bachert C: Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006;61:1280–1289.
28.
Van Bruaene N: T cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol 2008;121:S72.
29.
Loesel LS: Immunopathologic study of chronic sinusitis: a proposal for atopic and non-atopic IgE-activated mast cell allergic inflammation. Ann Otol Rhinol Laryngol 2001;110:447–452.
30.
Drake-Lee A, Price J: Mast cell ultrastructure in the inferior turbinate and stroma of nasal polyps. J Laryngol Otol 1997;111:340–345.
31.
Kowalski ML, Lewandowska-Polak A, Woźniak J, Ptasińska A, Jankowski A, Wagrowska-Danilewicz M, Danilewicz M, Pawliczak R: Association of stem cell factor expression in nasal polyp epithelial cells with aspirin sensitivity and asthma. Allergy 2005;60:631–637.
32.
Bachert C, Wagenmann M, Hauser U, Rudack C: IL-5 synthesis is upregulated in human nasal polyp tissue. J Allergy Clin Immunol 1997;99:837–842.
33.
Hamilos DL, Leung DY, Wood R, Bean DK, Song YL, Schotman E, Hamid Q: Eosinophil infiltration in nonallergic chronic hyperplastic sinusitis with nasal polyposis (CHS/NP) is associated with endothelial VCAM-1 upregulation and expression of TNF-alpha. Am J Respir Cell Mol Biol 1996;15:443–450.
34.
Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K: Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997;158:3902–3908.
35.
Bachert C, Gevaert P, Holtappels G, Cuvelier C, van Cauwenberge P: Nasal polyposis: from cytokines to growth. Am J Rhinol 2000;14:279–290.
36.
Meyer JE, Bartels J, Görögh T, Sticherling M, Rudack C, Ross DA, Maune S: The role of RANTES in nasal polyposis. Am J Rhinol 2005;19:15–20.
37.
Jahnsen FL, Haraldsen G, Aanesen JP, Haye R, Brandtzaeg P: Eosinophil infiltration is related to increased expression of vascular cell adhesion molecule-1 in nasal polyps. Am J Respir Cell Biol 1995;12:624–632.
38.
Pawankar R: Nasal polyposis: an update. Curr Opin Allergy Clin Immunol 2003;3: 1–6.
39.
Tos M, Sasaki Y, Ohnishi M, Larsen P, Drake-Lee AB: Fireside conference 2. Pathogenesis of nasal polyps. Rhinol Suppl 1992:14;181–185.
40.
Ponikau JU, Sherris DA, Kern EB, Homburger HA, Frigas E, Gaffey TA, Roberts GD: The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 1999;74:877–884.
41.
Zhang N, Gevaert P, van Zele T, Perez-Novo C, Patou J, Holtappels G, van Cauwenberge P, Bachert C: An update on the impact of Staphylococcus aureus enterotoxins in chronic sinusitis with nasal polyposis. Rhinology 2005;43:162–168.
42.
Bachert C, Zhang N, Patou J, van Zele T, Gevaert P: Role of staphylococcal superantigens in upper airway disease. Curr Opin Allergy Clin Immunol 2008;8:34–38.
43.
Bachert C, van Zele T, Gevaert P, De Schrijver L, Van Cauwenberge P: Superantigens and nasal polyps. Curr Allergy Asthma Rep 2003;3:523–531.
44.
Van Zele T, Gevaert P, Watelet JB, Claeys G, Holtappels G, Claeys C, van Cauwenberge P, Bachert C: Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol 2004;114:981–983.
45.
Patou J, Gevaert P, Van Zele T, Holtappels G, van Cauwenberge P, Bachert C: Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps. J Allergy Clin Immunol 2008;121:110–115.
46.
Van Zele T, Gevaert P, Holtappels G, van Cauwenberge P, Bachert C: Local immunoglobulin production in nasal polyposis is modulated by superantigens. Clin Exper Allergy 2007;37:1840–1847.
47.
Pérez-Novo CA, Claeys C, Van Zele T, Holtapples G, Van Cauwenberge P, Bachert C: Eicosanoid metabolism and eosinophilic inflammation in nasal polyp patients with immune response to Staphylococcus aureus enterotoxins. Am J Rhinol 2006;20:456–460.
48.
Blomqvist EH, Lundblad L, Änggård A, Haraldsson PO, Stjärne P: A randomized controlled study evaluating medical treatment versus surgical treatment in addition to medical treatment of nasal polyposis. J Allergy Clin Immunol 2001;107:224–228.
49.
Blomqvist EH, Lundblad L, Bergstedt H, Stjärne P: A randomized prospective study comparing medical and medical-surgical treatment of nasal polyposis by CT. Acta Otolaryngol 2009;129:545–549.
50.
Dalziel K, Stein K, Round A, Garside R, Royle P: Endoscopic sinus surgery for the excision of nasal polyps: a systematic review of safety and effectiveness. Am J Rhinol 2006;20:506–519.
51.
Hopkins C, Browne JP, Slack R, Lund V, Topham J, Reeves B, Copley L, Brown P, van der Meulen J: The national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Clin Otolaryngol 2006;31:390–398.
52.
Wynn R, Har-El G: Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope 2004;114:811–813.
53.
Vento SI, Ertama LO, Hytönen ML, Wolff CH, Malmberg CH: Nasal polyposis: clinical course during 20 years. Ann Allergy Asthma Immunol 2000;85:209–214.
54.
Badia L, Lund V: Topical corticosteroids in nasal polyposis. Drugs 2001;61:573–578.
55.
Mullol J, Xaubet A, López E, Roca-Ferrer J, Picado C: Comparative study of the effects of different glucocorticosteroids on eosinophil survival primed by cultured epithelial cell supernatants obtained from nasal mucosa and nasal polyps. Thorax 1995;50:270–274.
56.
Xaubet A, Mullol J, Roca-Ferrer J, Pujols L, Fuentes M, Pérez M, Fabra JM, Picado C: Effect of budesonide and nedocromil sodium on IL-6 and IL-8 release from human nasal mucosa and polyp epithelial cells. Respir Med 2001;95:408–414.
57.
Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE: Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol 1999;163:1545–1551.
58.
Benson M: Pathophysiological effects of glucocorticoids on nasal polyps: an update. Curr Opin Allergy Clin Immunol 2005;5:31–35.
59.
Benítez P, Alobid I, de Haro J, Berenguer J, Bernal-Sprekelsen M, Pujols L, Picado C, Mullol J: A short course of oral prednisone followed by intranasal budesonide is an effective treatment of severe nasal polyps. Laryngoscope 2006;116:770–775.
60.
Hissaria P, Smith W, Wormald PJ, Taylor J, Vadas M, Gillis D, Kette F: Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clin Immunol 2006;118:128–133.
61.
Alobid I, Benitez P, Pujols L, Maldonado M, Bernal-Sprekelsen M, Morello A, Picado C, Mullol J: Severe nasal polyposis and its impact on quality of life. The effect of a short course of oral steroids followed by long-term intranasal corticosteroid treatment. Rhinology 2006;44:8–13.
62.
Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S, Hens G, Hellings P, Ebbens FA, Fokkens W, Van Cauwenberge P, Bachert C: Oral steroids and doxycycline in nasal polyps: a 3-month double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol (in press).
63.
Bonfils P, Halimi P, Malinvaud D: Adrenal suppression and osteoporosis after treatment of nasal polyposis. Acta Otolaryngol 2006;126:1195–1200.
64.
Mygind N, Pedersen CB, Prytz S, Sørensen H: Treatment of nasal polyps with intranasal beclomethasone dipropionate aerosol. Clin Allergy 1975;5:159–164.
65.
Deuschl H, Drettner B: Nasal polyps treated by beclomethasone nasal aerosol. Rhinology 1977;15:17–23.
66.
Holopainen E, Grahne B, Malmberg H, Mäkinien J, Lindqvist N: Budesonide in the treatment of nasal polyposis. Eur J Respir Dis Suppl 1982;122:221–228.
67.
Vendelbo Johansen L, Illum P, Kristensen S, Winther L, Vang Petersen S, Synnerstad B: The effect of budesonide (Rhinocort®) in the treatment of small and medium-sized nasal polyps. Clin Otolaryngol Allied Sci 1993;18:524–527.
68.
Lildholt T, Rundcrantz H, Lindqvist N: Efficacy of topical corticosteroid powder for nasal polyps: a double-blind, placebo-controlled study of budesonide. Clin Otolaryngol Allied Sci 1995;20:26–30.
69.
Holmberg K, Juliusson S, Balder B, Smith DL, Richards DH, Karlsson G: Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann Allergy Asthma Immunol 1997;78:270–276.
70.
Tos M, Svendstrup F, Arndal H, Orntoft S, Jakobsen J, Borum P, Schrewelius C, Larsen PL, Clement F, Barfoed C, Rømeling F, Tvermosegaard T: Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol 1998;12:183–189.
71.
Lund VJ, Flood J, Sykes AP, Richards DH: Effect of fluticasone in severe polyposis. Arch Otolaryngol Head Neck Surg 1998;124:513–518.
72.
Keith P, Nieminen J, Hollingworth K, Dolovich J: Efficacy and tolerability of fluticasone propionate nasal drops 400 microgram once daily compared with placebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy 2000;30:1460–1468.
73.
Penttilä M, Poulsen P, Hollingworth K, Holmström M: Dose-related efficacy and tolerability of fluticasone propionate nasal drops 400 µg once daily and twice daily in the treatment of bilateral nasal polyposis: a placebo-controlled randomized study in adult patients. Clin Exp Allergy 2000;30:94–102.
74.
Hadfield PJ, Rowe-Jones JM, Mackay IS: A prospective treatment trial of nasal polyps in adults with cystic fibrosis. Rhinology 2000;38:63–65.
75.
Stjärne P, Mösges R, Jorissen M, Passàli D, Bellussi L, Staudinger H, Danzig M: A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis. Arch Otolaryngol Head Neck Surg 2006;132:179–185.
76.
Stjärne P, Blomgren K, Cayé-Thomasen P, Salo S, Søderstrøm T: The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo controlled study. Acta Otolaryngol 2006;126:606–612.
77.
Joe SA, Thambi R, Huang J: A systematic review of the use of intranasal steroids in the treatment of chronic rhinosinusitis. Otolaryngol Head Neck Surg 2008;139:340–347.
78.
Aukema AAC, Mulder PGH, Fokkens WJ: Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery. J Allergy Clin Immunol 2005;115:1017–1023.
79.
Virolainen E, Puhakka H: The effect of intranasal beclomethasone dipropionate on the recurrence of nasal polyps after ethmoidectomy. Rhinology 1980;18:9–18.
80.
Karlsson G, Rundcrantz H: A randomized trial of intranasal beclomethasone dipropionate after polypectomy. Rhinology 1982;20:144–148.
81.
Drettner B, Ebbesen A, Nilsson M: Prophylactive treatment with flunisolide after polypectomy. Rhinology 1982;20:149–158.
82.
Dingsør G, Kramer J, Olsholt R, Søderstrøm T: Flunisolide nasal spray 0.025% in the prophylactic treatment of nasal polyposis after polypectomy. A randomized, double blind, parallel, placebo controlled study. Rhinology 1985;23:49–58.
83.
Hartwig S, Lindén M, Laurent C, Vargö AK, Lindqvist N: Budesonide nasal spray as prophylactic treatment after polypectomy (a double blind clinical trial). J Laryngol Otol 1988;102:148–151.
84.
Dijkstra MD, Ebbens FA, Poublon RM, Fokkens WJ: Fluticasone propionate aqueous nasal spray does not influence the recurrence rate of chronic rhinosinusitis and nasal polyps 1 year after functional endoscopic sinus surgery. Clin Exp Allergy 2004;34:1395–1400.
85.
Rowe-Jones JM, Medcalf M, Durham SR, Richards DH, Mackay IS: Functional endoscopic sinus surgery: 5 year follow up and results of a prospective, randomised, stratified, double-blind, placebo controlled study of postoperative fluticasone propionate aqueous nasal spray. Rhinology 2005;43:2–10.
86.
Stjärne P, Olsson P, Alenius M: Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery. Arch Otolaryngol Head Neck Surg 2009;135:296–302.
87.
Jorissen M, Bachert C: Effect of corticosteroids on wound healing after endoscopic sinus surgery. Rhinology 2009;47:280–286.
88.
Stanbury RM, Graham EM: Systemic corticosteroid therapy: side effects and their management. Br J Ophthalmol 1998;82:704–708.
89.
Zitt M, Kosoglou T, Hubbell J: Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf 2007;30:317–326.
90.
Allen DB: Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol 2000;106(suppl 4): S179–S190.
91.
Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol 1999;104:S150–S158.
92.
Daley-Yates PT, McAllister T: Systemic bioavailability of fluticasone propionate administered as nasal drops (FP-Drops) and aqueous nasal spray formulations (FPANS) (abstract). Allergy 1998;53:158.
93.
Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, Storms WW, Wood RA: Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000;105:E23.
94.
Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A, Rosen JP, Ruff ME, Vandewalker ML, Wanderer A, Damaraju CV, Nolop KB, Mesarina-Wicki B: Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000;105:E22.
95.
Allen DB, Meltzer EO, Lemanske RF Jr, Philpot EE, Faris MA, Kral KM, Prillaman BA, Rickard KA: No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002;23:407–413.
96.
Ober S, Gentile D, Kairis E, Barnoski K, Doyle W, Skoner D: Growth velocity and HPA axis function during 1-year treatment with triamcinolone acetonide aqueous (TAA) nasal spray in children with allergic rhinitis (AR) (abstract 1064). J Allergy Clin Immunol 2005;115(suppl):S267.
97.
Murphy K, Uryniak T, Simpson B, O’Dowd L: Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol 2006;96:723–730.
98.
Gradman J, Caldwell MF, Wolthers OD: A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis. Clin Ther 2007;29:1738–1747.
99.
Rosenblut A, Bardin PG, Muller B, Faris MA, Wu WW, Caldwell MF, Fokkens WJ: Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007;62:1071–1077.
100.
Salib RJ, Howarth PH: Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003;26:863–893.
101.
Schenkel E: Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis. Expert Opin Pharmacother 2003;4:1579–1591.
102.
Meltzer EO, Bachert C, Staudinger H: Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol 2005;116:1289–1295.
103.
Rhinocort Aqua (package insert). Wilmington, AstraZeneca LP, 2004.
104.
Benninger MS, Hadley JA, Osguthorpe JD, Marple BF, Leopold DA, Derebery MJ, Hannley M: Techniques of intranasal steroid use. Otolaryngol Head Neck Surg 2004;130:5–24.
105.
Passáli D, Bernstein JM, Passali FM, Damiani V, Passàli GC, Bellussi L: Treatment of recurrent chronic hyperplastic sinusitis with nasal polyposis. Arch Otolaryngol Head Neck Surg 2003;129:656–659.
106.
Kieff DA, Busaba NY: Efficacy of montelukast in the treatment of nasal polyposis. Ann Otol Rhinol Laryngol 2005;114:941–945.
107.
Mostafa BE, Abdel Hay H, Mohammed HE, Yamani M: Role of leukotriene inhibitors in the postoperative management of nasal polyps. ORL J Otorhinolaryngol Relat Spec 2005;67:148–153.
108.
Zheng C, Wang Z, Lacroix JS: Effect of intranasal treatment with capsaicin on the recurrence of polyps after polypectomy and ethmoidectomy. Acta Otolaryngol 2000;120:62–66.
109.
Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, Holtappels G, Tavernier J, van Cauwenberge P, Bachert C: Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006;118:1133–1141.
110.
Parikh AA, Scadding GK: Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial. Laryngoscope 2005;115:1385–1390.
111.
Ogata N, Darby Y, Scadding G: Intranasal lysine-aspirin administration decreases polyp volume in patients with aspirin-intolerant asthma. J Laryngol Otol 2007;121:1156–1160.
112.
Weschta M, Rimek D, Formanek M, Polzehl D, Podbielski A, Riechelmann H: Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: a randomized, double-blind clinical trial. J Allergy Clin Immunol 2004;113:1122–1128.
113.
Ponikau JU, Sherris DA, Weaver A, Kita H: Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunol 2005;115:125–131.
114.
Ebbens FA, Scadding GK, Badia L, Hellings PW, Jorissen M, Mullol J, Cardesin A, Bachert C, van Zele TP, Dijkgraaf MG, Lund V, Fokkens WJ: Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis. J Allergy Clin Immunol 2006;118:1149–1156.
115.
Kanowitz SJ, Batra PS, Citardi MJ: Topical budesonide via mucosal atomization device in refractory postoperative chronic rhinosinusitis. Otolaryngol Head Neck Surg 2008;139:131–136.
116.
Mepolizumab (Adis R&D Profile). Drugs RD 2008;9:125–130.
117.
Verbruggen K, Van Cauwenberge P, Bachert C: Anti-IgE for the treatment of allergic rhinitis – and eventually nasal polyps? Int Arch Allergy Immunol 2009;148:87–98.
118.
Rasp G: Influence of anti-IgE on nasal polyps. J Allergy Clin Immunol 2007;119:S56.
119.
Watelet JB, Bachert C, Claeys C, Van Cauwenberge P: Matrix metalloproteinases MMP-7, MMP-9 and their tissue inhibitor TIMP-1: expression in chronic sinusitis versus nasal polyposis. Allergy 2004;59:54–60.
120.
Huvenne W, Zhang N, Tijsma E, Hissong B, Huurdeman J, Holtappels G, Claeys S, Van Cauwenberge P, Nelis H, Coenye T, Bachert C: Pilot study using doxycycline-releasing stents to ameliorate postoperative healing quality after sinus surgery. Wound Repair Regen 2008;16:757–767.
121.
Kato Y, Fujisawa T, Shibano M, Saito T, Gatto W, Kamiya H, Hirai K, Sumida M, Yoshie O: Airway epithelial cells promote transmigration of eosinophils in a new three- dimensional chemotaxis model. Clin Exp Allergy 2002;32:889–897.
122.
Taylor-Clark T, Salagean EM, Salib R, Lau L, DiGiovanna I, Brennan N, Hewitt L, Periera S, Darby Y, Powell J, Scadding G, Howarth PH: The influence of intranasal pre-treatment with anti-eotaxin monoclonal antibody, CAT-213, on the nasal response to allergen challenge in rhinitis (abstract). Allergy 2003;58(suppl 74):6.
123.
Hamilos DL, Thawley SE, Kramper MA, Kamil A, Hamid QA: Effect of intranasal fluticasone on cellular infiltration, endothelial adhesion molecule expression, and proinflammatory cytokine mRNA in nasal polyp disease. J Allergy Clin Immunol 1999;103:79–87.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.